These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25505415)

  • 1. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability.
    Chetty M; Rose RH; Abduljalil K; Patel N; Lu G; Cain T; Jamei M; Rostami-Hodjegan A
    Front Pharmacol; 2014; 5():258. PubMed ID: 25505415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.
    Alqahtani S; Kaddoumi A
    Clin Pharmacokinet; 2016 Aug; 55(8):957-69. PubMed ID: 26914771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets.
    Paraiso RLM; Rose RH; Fotaki N; McAllister M; Dressman JB
    Eur J Pharm Sci; 2020 Dec; 155():105534. PubMed ID: 32871212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
    Wang B; Liu Z; Li D; Yang S; Hu J; Chen H; Sheng L; Li Y
    Eur J Pharm Sci; 2015 Sep; 77():265-72. PubMed ID: 26116279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption.
    Kesisoglou F; Balakrishnan A; Manser K
    J Pharm Sci; 2016 Feb; 105(2):722-728. PubMed ID: 26457884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
    Ganti A; Yu S; Sharpnack D; Ingalla E; De Bruyn T
    Biopharm Drug Dispos; 2023 Aug; 44(4):301-314. PubMed ID: 37102506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
    Tylutki Z; Mendyk A; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.
    Lee W; Kim MS; Kim J; Aoki Y; Sugiyama Y
    Drug Metab Dispos; 2023 Sep; 51(9):1145-1156. PubMed ID: 36914276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Qualification of a Physiologically Based Pharmacokinetic Model of Finasteride and Minoxidil Following Scalp Application.
    Ngampanya A; Udomnilobol U; Sermsappasuk P; Pornputtapong N; Ongpipattanakul B; Patel N; Jianmongkol S; Prueksaritanont T
    J Pharm Sci; 2021 May; 110(5):2301-2310. PubMed ID: 33609522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.